A new screening of preterm birth in gestation with short cervix after pessary plus progesterone

Rev Bras Ginecol Obstet. 2024 Sep 6:46:e-rbgo39i. doi: 10.61622/rbgo/2024rbgo39i. eCollection 2024.

Abstract

Objective: This study aims to create a new screening for preterm birth < 34 weeks after gestation with a cervical length (CL) ≤ 30 mm, based on clinical, demographic, and sonographic characteristics.

Methods: This is a post hoc analysis of a randomized clinical trial (RCT), which included pregnancies, in middle-gestation, screened with transvaginal ultrasound. After observing inclusion criteria, the patient was invited to compare pessary plus progesterone (PP) versus progesterone only (P) (1:1). The objective was to determine which variables were associated with severe preterm birth using logistic regression (LR). The area under the curve (AUC), sensitivity, specificity, and positive predictive value (PPV) and negative predictive value (NPV) were calculated for both groups after applying LR, with a false positive rate (FPR) set at 10%.

Results: The RCT included 936 patients, 475 in PP and 461 in P. The LR selected: ethnics white, absence of previous curettage, previous preterm birth, singleton gestation, precocious identification of short cervix, CL < 14.7 mm, CL in curve > 21.0 mm. The AUC (CI95%), sensitivity, specificity, PPV, and PNV, with 10% of FPR, were respectively 0.978 (0.961-0.995), 83.4%, 98.1%, 83.4% and 98.1% for PP < 34 weeks; and 0.765 (0.665-0.864), 38.7%, 92.1%, 26.1% and 95.4%, for P < 28 weeks.

Conclusion: Logistic regression can be effective to screen preterm birth < 34 weeks in patients in the PP Group and all pregnancies with CL ≤ 30 mm.

Keywords: Cervix uteri; Logistic models; Pessaries; Preterm birth; Progesterone; Screening; Ultrasonography.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cervical Length Measurement*
  • Cervix Uteri* / diagnostic imaging
  • Female
  • Humans
  • Pessaries*
  • Pregnancy
  • Premature Birth* / prevention & control
  • Progesterone* / administration & dosage
  • Progestins* / administration & dosage

Substances

  • Progesterone
  • Progestins